Phase 3 trial of Breztri in easing cardiopulmonary problems opens
A Phase 3 clinical trial assessing the potential of triple-combination Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) to improve cardiopulmonary outcomes in people with chronic obstructive pulmonary disease (COPD) is opening at sites worldwide, AstraZeneca, which markets the inhaled therapy, announced. The THARROS study (NCT06283966) is expected to enroll up…